Low-dose zoledronic acid appeared safe among older patients with hip fracture and advanced chronic kidney disease.

December 16, 2010 — Treatment with zoledronic acid (Zometa) appears to have benefits beyond bone health in patients with multiple myeloma. Researchers in the United Kingdom report that overall ...

Bone metastases cause patient morbidity and mortality. A recent study compared denosumab with zoledronic acid for the treatment of bone metastases in advanced breast cancer. Denosumab seemed to be the ...

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Zoledronic Acid Injection, USP in ...

RTOG 0518 evaluated the potential benefit of zoledronic acid therapy in preventing bone fractures for patients with high grade and/or locally advanced, non-metastatic prostate adenocarcinoma receiving ...

Please provide your email address to receive an email when new articles are posted on . Individuals undergoing treatment for cancer are known to be at greater risk for bone loss, subsequent ...

Please provide your email address to receive an email when new articles are posted on . A single dose of zoledronic acid effectively maintains large and rapid gains in spine and hip bone mineral ...

Zoledronic acid administration during the initial hospitalization for osteoporotic hip fracture significantly reduces all-cause mortality and subsequent vertebral fractures among older patients.

June 4, 2009 — The FDA this month has approved zoledronic acid infusion (Reclast, Novartis Pharmaceuticals Corp) for the prevention of postmenopausal osteoporosis during a 2-year period. "It is very ...

Comparison of the postoperative prognostic value between old (6th edition) and new (7th edition) UICC TNM classification for renal cell carcinoma. Background: Bone metastases occur in almost 40% of ...

Review the side-effects of Zoledronic Acid as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

Bisphosphonates are effective agents for the management of osteoporosis. Their low bioavailability and low potency necessitate frequent administration on an empty stomach, which may reduce compliance.